Selank, Semax, and DSIP: The Cognitive Performance and Sleep Stack (2026)

Educational guide for research and informational purposes only. Not medical advice.

The cognitive and anxiolytic peptides occupy a distinct niche in the peptide landscape. Where GLP-1s and GH secretagogues target body composition, and recovery peptides address tissue repair, compounds like Selank, Semax, and DSIP work at the level of neurotransmitter systems, neurotrophic signaling, and sleep architecture. The outcomes they pursue — reduced anxiety, improved working memory, better sleep quality, and neuroplasticity — are harder to quantify than body fat percentage or lean mass, but no less significant for performance and longevity.

All three originate from Soviet-era Russian pharmacology research and have a clinical use history in Russia and Eastern Europe that predates Western peptide research by decades.

Selank — Anxiolytic Neuropeptide with Nootropic Properties

Origin and Structure

Selank is a synthetic heptapeptide analog of the endogenous immunomodulatory peptide tuftsin. Tuftsin is a tetrapeptide (Thr-Lys-Pro-Arg) with immunostimulatory properties; Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) extends this structure with a Pro-Gly-Pro sequence that dramatically extends its stability and CNS penetrability. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is clinically approved in Russia for treatment of anxiety and asthenic disorders.

Mechanisms of Action

Selank's pharmacology is multifaceted and distinguishes it from conventional anxiolytics (benzodiazepines, SSRIs):

• GABAergic modulation — Selank modulates GABA-A receptor function similarly to benzodiazepines but without binding the benzodiazepine site directly; this produces anxiolysis without the sedation, tolerance, or dependence associated with classic benzodiazepine use
• BDNF upregulation — brain-derived neurotrophic factor is the primary mediator of neuroplasticity, long-term potentiation, and learning consolidation; Selank reliably increases BDNF mRNA expression in animal models
• Enkephalin regulation — Selank inhibits enkephalinase enzymes, increasing the availability of endogenous enkephalins (endogenous opioid peptides that modulate pain, stress, and emotional tone)
• Serotonin metabolism — modulates 5-HT turnover in limbic regions; this likely contributes to mood stabilization effects without the receptor downregulation seen with SSRIs
• Immune modulation — as a tuftsin analog, Selank influences cytokine balance (IL-6, IFN-γ) — the neuroinflammation connection that links immune dysfunction to anxiety and cognitive impairment

Clinical Research

Russian clinical trials have examined Selank in generalized anxiety disorder, asthenic syndrome, and PTSD-adjacent anxiety presentations. Key findings:

• Anxiolytic effect comparable to benzodiazepines (phenazepam) without sedation, motor impairment, or tolerance
• Improvements in working memory, concentration, and cognitive processing speed in subjects with anxiety-impaired cognition
• Stabilization of mood without blunting or emotional anesthesia reported in clinical series
• BDNF elevation maintained over treatment course — suggesting progressive neuroplastic benefit rather than tolerance

Protocol Parameters

• Dose: 250–500mcg intranasal, 1–2x daily; or subcutaneous at similar doses
• Intranasal delivery preferred for CNS effects — olfactory route provides direct brain access
• Duration: 10–14 day courses followed by equal rest period; or lower-dose continuous use
• Onset: 20–40 minutes; duration: 4–6 hours
• No reported dependence or withdrawal syndrome in clinical literature

Semax — Cognitive Enhancer and Neuroprotective Agent

Origin and Structure

Semax is a synthetic heptapeptide derived from the N-terminal fragment of ACTH (adrenocorticotropin hormone): specifically, ACTH(4-7) with a Pro-Gly-Pro extension that, like Selank, stabilizes the peptide against rapid degradation. Unlike ACTH, Semax has no adrenocortical activity — it does not raise cortisol. Its effects are entirely neurological.

Semax is approved in Russia for treatment of stroke, transient ischemic attack, cognitive disorders, and optic nerve pathology. It has been in clinical use for over 25 years, providing a more extensive real-world safety database than most research peptides.

Mechanisms of Action

• BDNF and NGF induction — Semax is one of the most potent inducers of BDNF and NGF (nerve growth factor) in the peptide category. These neurotrophins drive synaptogenesis, axonal growth, and the cellular mechanisms of learning and memory consolidation. A single intranasal dose of Semax has been shown to increase hippocampal BDNF mRNA by 1.4–2.5x in rodent models
• Dopaminergic and serotonergic modulation — Semax increases turnover of dopamine and serotonin in prefrontal cortex and hippocampus; this underlies its nootropic and mood-stabilizing effects
• Nitric oxide regulation — modulates NOS (nitric oxide synthase) activity in cerebrovascular tissue; this improves cerebral blood flow and is likely the mechanism underlying its utility post-stroke
• Neuroprotection — in models of ischemia, excitotoxicity, and oxidative stress, Semax reduces neuronal death and preserves function. This is relevant both for clinical neuroprotection (stroke, TBI) and for the general goal of maintaining cognitive resilience under metabolic and oxidative stress
• Memory and learning enhancement — improved performance on spatial memory tasks, working memory, and executive function tasks in both animal models and small human studies

Protocol Parameters

• Dose: 200–600mcg intranasal, 1–2x daily (divided morning and midday)
• Intranasal delivery preferred; subcutaneous is an alternative
• Courses: typically 10–14 days on, 2 weeks off (to preserve sensitivity)
• Best timed in the morning for cognitive effects — can be slightly activating and is not recommended at night
• Well-tolerated; most reported effects are cognitive enhancement, improved focus, and mood stabilization

DSIP (Delta Sleep-Inducing Peptide) — Sleep Architecture Modulator

What DSIP Is

DSIP is a nonapeptide (9 amino acids) first isolated from rabbit brains in 1977 by Monnier and colleagues, initially in the context of research into sleep-inducing factors. Its name reflects its original characterization — it was isolated from venous blood of rabbits during slow-wave sleep and produced EEG patterns consistent with delta-wave sleep when administered to other animals.

The neurobiology of DSIP is more complex than its name implies. It is not simply a sedative — it modulates the entire sleep architecture, particularly promoting the slow-wave (deep) sleep stages where the majority of physical recovery and growth hormone secretion occur.

Mechanisms of Action

• Delta wave (Stage 3/4) sleep promotion — DSIP selectively increases slow-wave sleep time and reduces sleep latency; does not produce the rebound insomnia or REM suppression seen with benzodiazepines
• GH pulse amplification — deep sleep is the primary trigger for nocturnal GH release; by increasing slow-wave sleep time, DSIP indirectly augments the nightly GH pulse that drives recovery and anabolism
• Stress axis normalization — DSIP modulates CRH (corticotropin-releasing hormone) activity and reduces ACTH/cortisol responses to stress; animals under chronic stress show normalization of cortisol with DSIP treatment
• Antioxidant activity — DSIP has been shown to reduce lipid peroxidation and protect against oxidative stress in several tissue types
• Antinociception — pain modulation through opioid-adjacent pathways; may reduce the sleep disruption caused by pain

Why Sleep Architecture Matters for Performance

Sleep quality is one of the primary limiting factors in athletic recovery, cognitive performance, and hormonal health. Specifically:

• Slow-wave sleep is when 70–80% of the daily GH secretion occurs — the pulse that repairs muscle, reduces fat mass, and maintains metabolic function
• REM sleep consolidates procedural memory, emotional regulation, and motor pattern learning
• Sleep deprivation reduces testosterone by 15–25% in a single week (Leproult & Van Cauter, 2011)
• Cortisol dysregulation from poor sleep directly impairs muscle protein synthesis and increases VAT accumulation

DSIP addresses the quality of the foundational recovery process — not by sedating, but by improving the architecture of sleep itself.

Protocol Parameters

• Dose: 100–300mcg subcutaneous, 30–60 minutes before sleep
• Not sedating in the benzodiazepine sense — produces natural sleep induction rather than forced sedation
• Cycle: intermittent use (3–5x per week) rather than nightly; tolerance profile unknown with daily use
• Can stack directly with CJC-1295/Ipamorelin (also pre-sleep) for combined GH pulse enhancement and sleep quality improvement

Comparison and Stack Integration

These three compounds create a complete cognitive and recovery architecture: Semax optimizes daytime cognitive performance; Selank manages anxiety and stress reactivity that impairs performance and sleep; DSIP ensures the recovery process during sleep is maximally efficient. Running them together does not create redundancy — they address different timescales and mechanisms of the same goal.

Cognitive Performance Stack

• Morning: Semax 400mcg intranasal + Selank 250mcg intranasal
• Pre-sleep: DSIP 200mcg SC + CJC-1295/Ipamorelin (for GH pulse amplification)

References

1. Semenova TP, et al. Selank and Its Constituent Peptide Thr-Lys-Pro-Arg-Pro-Gly-Pro Enhance Serotonin Metabolism in the Brain of Rats. Bull Exp Biol Med. 2009;147(4):479–482.
2. Kaplan AY, et al. Peptide Selank Induces Changes in the Activity State of Neurons in the Brain. Int J Peptide Res Ther. 2005.
3. Dolotov OV, et al. Semax, an Analog of ACTH(4–7), Regulates BDNF and trkB Expression in the Rat Hippocampus. Front Cell Neurosci. 2006.
4. Menshanov PN, et al. Neuroprotective Properties of Semax in Focal Ischemia. Bull Exp Biol Med. 2010;149(1):74–77.
5. Monnier M, Dudler L, Gächter R, et al. The Delta Sleep-Inducing Peptide (DSIP). Experientia. 1977;33(4):548–552.
6. Leproult R, Van Cauter E. Effect of 1 Week of Sleep Restriction on Testosterone Levels. JAMA. 2011;305(21):2173–2174.

Educational Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before initiating any peptide protocol.

FitAF Performance — Educational content only.